FloraWorks Announces Updated Analysis of Landmark Clinical Trial; CBN Shown Effective for Sleep

In a recent groundbreaking clinical trial conducted by Radicle Science, FloraWorks Holdings Inc. has shared the remarkable results of treating sleep disturbances. This industry-first, double-blind, randomized, placebo-controlled trial examined the effects of TruCBN™ at varying doses of 25, 50, and 100 milligrams. The findings revealed significant improvements in sleep outcomes and clinically meaningful enhancements.

“The historical firsts encompassed in this study have tremendous implications for formulating effective, natural sleep products for Americans. The findings especially highlight the importance of understanding the appropriate dosage for the desired health outcome. For CBN, higher concentrations like 100 mg do not seem to improve effectiveness for sleep disturbance compared to lower concentrations like 50 mg. This is some of the first human data to suggest CBN can significantly improve sleep, and the effects may be comparable to the most studied and used dietary supplement sleep ingredient: melatonin. It highlights the importance of exploring product formulations in a methodical, clinical manner through randomized, blinded clinical trials.” – Dr. Jeff Chen

 

 

Read More